Daniel Fábio Kawano

Dr. Daniel Fábio Kawano


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
VSValéria Barbosa de Souza
Valéria Barbosa de Souza
DKDaniel Fábio Kawano
Daniel Fábio Kawano

1 February 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
PBPrzemysław Biegański
Przemysław Biegański
MGMartina Godel
Martina Godel
Chiara RigantiChiara Riganti
Chiara Riganti
DKDaniel Fábio Kawano
Daniel Fábio Kawano
JKJoanna Kopecka
Joanna Kopecka
KKKonrad Kowalski
Konrad Kowalski

18 May 2017 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
LKLuciano Porto Kagami
Luciano Porto Kagami
GNGustavo Neves
Gustavo Neves
RRRicardo Pereira Rodrigues
Ricardo Pereira Rodrigues
VSVinicius Barreto da Silva
Vinicius Barreto da Silva
VEVera Lucia Eifler-Lima
Vera Lucia Eifler-Lima
DKDaniel Fábio Kawano
Daniel Fábio Kawano

5 December 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
MKMaria Eduarda Krummenauer
Maria Eduarda Krummenauer
WLWilliam Lopes
William Lopes
AGAne Wichine Acosta Garcia
Ane Wichine Acosta Garcia
ASAugusto Schrank
Augusto Schrank
SGSimone Gnoatto
Simone Gnoatto
MVMarilene Vainstein
Marilene Vainstein
Cryptococcus neoformans is an encapsulated yeast responsible for more than 180,000 deaths per year. The standard therapeutic approach against cryptococcosis is a combination of amphotericin B with flucytosine. In countries where cryptococcosis is most prevalent, 5-fluorocytosine is rarely available, and amphotericin B requires intravenous administration. C. neoformans biofilm formation is related to increased drug resistance, which is an important outcome for hospitalized patients. Here, we describe new molecules with anti-cryptococcal activity. A collection of 66 semisynthetic derivatives of ursolic acid and betulinic acid was tested against mature biofilms of C. neoformans at 25 µM. Out of these, eight derivatives including terpenes, benzazoles, flavonoids, and quinolines were able to cause damage and eradicate mature biofilms. Four terpene compounds demonstrated significative growth inhibition of C. neoformans. Our study identified a pentacyclic triterpenoid derived from betulinic acid (LAFIS13) as a potential drug for anti-cryptococcal treatment. This compound appears to be highly active with low toxicity at minimal inhibitory concentration and capable of biofilm eradication.

3 May 2020 in European Journal of Lipid Science and Technology
Verified
Journal Article
Closed access
PDF file
XNXisto Antonio de Oliveira Neto
Xisto Antonio de Oliveira Neto
AAAnna Carolina Schneider Alves
Anna Carolina Schneider Alves
RJReinaldo Antonio Dias Junior
Reinaldo Antonio Dias Junior
RRRicardo Pereira Rodrigues
Ricardo Pereira Rodrigues
MLMarcelo Lancellotti
Marcelo Lancellotti
DKDaniel Fábio Kawano
Daniel Fábio Kawano

29 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
DKDaniel Fábio Kawano
Daniel Fábio Kawano
BCBruna Z. Costa
Bruna Z. Costa
KRKatherine Romero-Orejón
Katherine Romero-Orejón
HLHugo Loureiro
Hugo Loureiro
DJDosil P. de Jesus
Dosil P. de Jesus
AMAnita Jocelyne Marsaioli
Anita Jocelyne Marsaioli
1-Pyrrolines are important intermediates of active natural products, such as the 2,5-dialkyl-1-pyrroline derivatives found in fire ant venoms. Here, 5-hexyl-2-methyl-3,4-dihydro-2H-pyrrole was synthesized by the enzymatic transamination/cyclization of 2,5-undecadione, and enantiodifferenciation was successfully achieved by capillary electrophoresis with sulfobutyl ether-β-cyclodextrin as the chiral selector. The rationale of the enantiomeric discrimination was based on the results of a docking simulation that revealed the higher affinity of (S)-5-hexyl-2-methyl-3,4-dihydro-2H-pyrrole for the sulfobutyl ether-β-cyclodextrin.